Literature DB >> 17188331

Patterns of recurrent hepatitis C after liver transplantation in a recent cohort of patients.

Urmila Khettry1, Weei-Yuan Huang, Mary Ann Simpson, Elizabeth A Pomfret, James J Pomposelli, W David Lewis, Roger L Jenkins, Fredric D Gordon.   

Abstract

Clinicopathologic trends of recurrent hepatitis C after liver transplantation (LT) in hepatitis C (HCV) patients seem to have changed in recent years. Our aims were to define the current post-LT patterns of HCV recurrence and identify features of diagnostic and/or prognostic significance. Detailed analysis was performed on 92 HCV patients who underwent LT from June 1999 to December 2003 and survived early post-LT period. The study patients were grouped, as follows: no histologic recurrence (n = 31), "typical" recurrent HCV (n = 52), and post-LT autoimmune-like hepatitis ("AIH-like") (n = 9). The typical and AIH-like groups had mostly common features with post-LT progressive fibrosis (stage > or =2) more frequent in the latter. Based on post-LT progressive fibrosis (stage > or =2), the 2 post-LT hepatitis categories were regrouped as progressive (n = 24) and nonprogressive (n = 37). High viral counts, HCV genotype 1, and native liver inflammation grade 2 or higher with plasmacytic periseptitis were more frequent in progressive cases than nonprogressive or nonrecurrent cases. Sex mismatch of male recipient and female donor was more common in nonrecurrent group. Overall, death rate was comparable in all groups; however, post-LT HCV-related deaths were more common in progressive cases. In conclusion (1) two thirds (66.2%) of HCV patients developed histologic hepatitis after LT with either typical or AIH-like features; (2) progressive fibrosis was seen in 39.3% of patients with post-LT hepatitis and 26% of the entire study group and was more frequent in AIH-like cases; (3) inflammation grade 2 or higher with plasmacytic periseptitis in native livers may be a predictor of post-LT progressive fibrosis; and (4) male recipient/female donor combination was more common in nonrecurrent cases.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17188331     DOI: 10.1016/j.humpath.2006.08.028

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  8 in total

Review 1.  Histopathological evaluation of recurrent hepatitis C after liver transplantation: a review.

Authors:  Francesco Vasuri; Deborah Malvi; Elisa Gruppioni; Walter F Grigioni; Antonia D'Errico-Grigioni
Journal:  World J Gastroenterol       Date:  2014-03-21       Impact factor: 5.742

2.  Interferon graft dysfunction: a final chapter for interferon and hepatitis C.

Authors:  Julie A Thompson; John R Lake
Journal:  Hepatol Int       Date:  2014-04-06       Impact factor: 6.047

Review 3.  De novo autoimmune hepatitis in liver transplant: State-of-the-art review.

Authors:  Ranka Vukotic; Giovanni Vitale; Antonia D'Errico-Grigioni; Luigi Muratori; Pietro Andreone
Journal:  World J Gastroenterol       Date:  2016-03-14       Impact factor: 5.742

Review 4.  Autoimmune Hepatitis in the Liver Transplant Graft.

Authors:  Eliza W Beal; Sylvester M Black; Anthony Michaels
Journal:  Clin Liver Dis       Date:  2017-05       Impact factor: 6.126

5.  PHOENIX: A randomized controlled trial of peginterferon alfa-2a plus ribavirin as a prophylactic treatment after liver transplantation for hepatitis C virus.

Authors:  Natalie Bzowej; David R Nelson; Norah A Terrault; Gregory T Everson; Lichen L Teng; Avinash Prabhakar; Michael R Charlton
Journal:  Liver Transpl       Date:  2011-05       Impact factor: 5.799

6.  Recurrent hepatitis C virus after transplant and the importance of plasma cells on biopsy.

Authors:  Eric R Kallwitz
Journal:  World J Gastroenterol       Date:  2013-01-14       Impact factor: 5.742

Review 7.  Transplantation in autoimmune liver diseases.

Authors:  Marcus Mottershead; James Neuberger
Journal:  World J Gastroenterol       Date:  2008-06-07       Impact factor: 5.742

8.  Predictors of disease recurrence post living donor liver transplantation in end stage chronic HCV patients.

Authors:  Mostafa K El Awady; Noha G Bader El Din; Mahmoud Abdel Aziz Riad; Moataza H Omran; Tawfeek H Abdelhafez; Tamer Mahmoud Elbaz; Shereen Shoukry Hunter; Reham M Dawood; Ashraf O Abdel Aziz
Journal:  Dis Markers       Date:  2014-02-18       Impact factor: 3.434

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.